SUBSCRIBE TODAY!
Subscribing entitles a reader to complete stories on all topics released as they happen, special features, confidential documents and access to the complete, searchable story archive online back to 2004.

Advertisement


Inside Views

Submit ideas to info [at] ip-watch [dot] ch!

We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website.

By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

1. You agree that you are fully responsible for the content that you post. You will not knowingly post content that violates the copyright, trademark, patent or other intellectual property right of any third party or which you know is under a confidentiality obligation preventing its publication and that you will request removal of the same should you discover that you have violated this provision. Likewise, you may not post content that is libelous, defamatory, obscene, abusive, that violates a third party's right to privacy, that otherwise violates any applicable local, state, national or international law, that amounts to spamming or that is otherwise inappropriate. You may not post content that degrades others on the basis of gender, race, class, ethnicity, national origin, religion, sexual preference, disability or other classification. Epithets and other language intended to intimidate or to incite violence are also prohibited. Furthermore, you may not impersonate others.

2. You understand and agree that Intellectual Property Watch is not responsible for any content posted by you or third parties. You further understand that IP Watch does not monitor the content posted. Nevertheless, IP Watch may monitor the any user-generated content as it chooses and reserves the right to remove, edit or otherwise alter content that it deems inappropriate for any reason whatever without consent nor notice. We further reserve the right, in our sole discretion, to remove a user's privilege to post content on our site. IP Watch is not in any manner endorsing the content of the discussion forums and cannot and will not vouch for its reliability or otherwise accept liability for it.

3. By submitting any contribution to IP Watch, you warrant that your contribution is your own original work and that you have the right to make it available to IP Watch for all purposes and you agree to indemnify IP Watch, its directors, employees and agents against all damages, legal fees and others expenses that may be incurred by IP Watch as a result of your breach of warranty or of these terms.

4. You further agree not to publish any personal information about yourself or anyone else (for example telephone number or home address). If you add a comment to a blog, be aware that your email address will be apparent.

5. IP Watch will not be liable for any loss including but not limited to the following (whether such losses are foreseen, known or otherwise): loss of data, loss of revenue or anticipated profit, loss of business, loss of opportunity, loss of goodwill or injury to reputation, losses suffered by third parties, any indirect, consequential or exemplary damages.

6. You understand and agree that the discussion forums are to be used only for non-commercial purposes. You may not solicit funds, promote commercial entities or otherwise engage in commercial activity in our discussion forums.

7. You acknowledge and agree that you use and/or rely on any information obtained through the discussion forums at your own risk.

8. For any content that you post, you hereby grant to IP Watch the royalty-free, irrevocable, perpetual, exclusive and fully sub-licensable license to use, reproduce, modify, adapt, publish, translate, create derivative works from, distribute, perform and display such content in whole or in part, world-wide and to incorporate it in other works, in any form, media or technology now known or later developed.

9. These terms and your posts and contributions shall be governed and interpreted in accordance with the laws of Switzerland (without giving effect to conflict of laws principles thereof) and any dispute exclusively settled by the Courts of the Canton of Geneva.

To What Extent Can Global IP Rules Be Responsive To Public Interest Demands? The Case Of The Treaty For The Visually Impaired

To what extent can global intellectual property rules address in an effective manner the needs of the most vulnerable members of society? This is the key question with which member states of the World Intellectual Property Organization (WIPO) are faced as they prepare to meet next week for a diplomatic conference, in Marrakesh, that should result in the adoption of a treaty to facilitate access to copyrighted works by visually impaired persons and persons with print disabilities.


Interview With Tanja Rajić: The Impact Of EU Enlargement On Trademark Practice In Croatia

Ten years after applying for membership, Croatia is finally joining the European Union on 1 July 2013. Tanja Rajić, senior associate at PETOSEVIC, explains how six years of accession negotiations and the adoption of the acquis communautaire have affected intellectual property protection in Croatia and prepared it for becoming a member state.





Latest Comments
  • We in India should not change our policy, speciall... »
  • We in India should not change our policy, speciall... »

  • For IPW Subscribers
    A directory of IP delegates in Geneva. Read more>

    A guide to Geneva-based public health and intellectual property organisations. Read More >

    Monthly Reporter

    The Intellectual Property Watch Monthly Reporter, published from 2004 to January 2011, is a 16-page monthly selection of the most important, updated stories and features, plus the People and News Briefs columns.

    The Intellectual Property Watch Monthly Reporter is available in an online archive on the IP-Watch website, available for IP-Watch Subscribers.

    Access the Monthly Reporter Archive >


    Would US Senate Patent Reform Bill Harmonise US Law With The World?

    Published on 16 March 2011 @ 12:38 am

    By and , Intellectual Property Watch

    The bill to reform United States patent law recently passed by the Senate purports to bring US law closer to laws of other major patent-filing nations. But how close would it come?

    On 8 March, the US Senate overwhelmingly passed the Patent Reform Act of 2011, S.23, the America Invents Act [pdf], which is aimed at promoting innovation and at reducing the staggering patent backlog of the US Patent and Trademark Office.

    One of the provisions of this Act is to change the current system which gives patent priority to parties claiming to be first inventors. It would instead give priority to inventors being first to file a patent application. There have been some doubts about the real effect of this switch.

    The companion bill could be introduced in the House of Representatives as soon as this month.

    According to the PatentlyO blog, the Senate measure includes:

    - The ability for the USPTO to set its own fees and to eliminate the practice of fee-diversion.
    - A transition to a first-to-file system
    - Broader leeway for third-party submissions with explanations during ex parte patent prosecution.
    - A new “first-window” post-grant patent opposition system with broader jurisdiction (but a shorter timeframe) than re-examinations.
    - A provision that eliminates certain tax strategy patents.

    PatentlyO said controversial damages limitations appear to have been removed from the bill prior to passage.

    Optimism from Europe, but Still Differences

    There has been some optimism in the international community over the steps taken by the Senate toward harmonisation, though differences would still exist between national laws.

    The Senate approval “potentially heralds a significant and exciting change in US patent practice that would have implications internationally,” said Jane Hollywood, a patent attorney at Kilburn & Strode LLP in the United Kingdom. From the patentee’s perspective, it is potentially positive as “increased uniformity across patent systems worldwide promotes consistency and predictability in terms of obtaining patent protection.”

    “Clearly,” Hollywood told Intellectual Property Watch, “the difference between ‘first to file’ versus ‘first to invent’ has many more implications and therefore the harmonisation of this aspect is important and would generally be welcomed by non-US applicants.”

    The proposed language for implementing “first to file” in the US is “at first glance very similar to the corresponding provisions in at least the European Patent Convention (EPC) and the UK Patents Act,” she said. “However, the ‘grace period’, traditionally part of US practice, has survived in the proposed America Invents Act and would continue to represent a significant difference between practice before at least the EPO and in the UK.”

    S.23 states that a claimed invention is novel provided it was not disclosed in a ‘printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention’ (Sec. 102), Hollywood said. “The effective filing date is defined in Sec. 2 of the same Act as meaning the actual filing date of the patent or the application or the filing date of the earliest application for which the parent or application is entitled to claim priority.”

    This is essentially the same as the EPC and the UK Patents Act, she said, which “both state that an invention shall be considered to be new if it does not form part of the state of the art, where the state of the art comprises everything made available to the public by means of a written or oral description, by use, or in any other way, before the date of filing of the application.”

    She pointed out that there are “a number of countries around the world where different types of grace periods are in existence and this is not generally problematic to applicants.”

    In general, “There are cogent arguments for a ‘first to invent’ system, particularly from the perspective of an individual inventor or a small company,” Hollywood said. “However, a non-US applicant will rarely plan to utilise the ‘first to invent’ provision, as their patent strategy will be based on the ‘first to file’ provisions already in place in every other patent system.” If the Act is implemented, “the substantial shift towards harmonisation of the US patent system with other patent systems round the world should be viewed with optimism.”

    Another View: No Impact

    Meanwhile, Greg Aharonian, editor of the Internet Patent News Service, argued that first-to-file would have “little to no impact on the costs of foreign patent acquisition, which are mostly driven by costly language translation fees, and having your specification and claims rewritten to the philosophies of foreign patent systems.”

    “If we gave up first-to-file in return for Japan, China, Brazil and others examining patent applications in English, that would be a great deal for big and small inventors,” he said in his blog.

    The fact that the bill would increase the patent office’s resources by enabling it to remain all the fees it collects would not speed up the review of patent applications, according to Aharonian, because that would require changing the USPTO workflow processes and management of patent application, and providing more tools and resources to patent examiners. Large companies would have to “stop clogging USPTO pipelines with crap applications,” he said in his signature phrase.

    View from a US Opponent

    Senator Dianne Feinstein, a California Democrat, in a floor statement explaining her failed amendment to remove the first-to-file provision from the bill, said the provision would undermine protection for small inventors who need time to understand and use the patent system to protect their inventions. She also questioned the notion that the bill harmonises US law with laws elsewhere.

    “This bill would not actually harmonise on patent priority says with that of the rest of the world,” she said. “Many first-to-file countries use a more extensive use of prior art to defeat a patent application and provide for greater prior user rights than this bill would provide, and Europe does not provide even the limited one year publication grace period that this year does.”

    She also highlighted the grace period provision and said the bill removes it too substantially to be useful to small inventors. Currently, a person’s right to their invention is protected for one year from describing their invention in a printed publication, making a public use of the invention, or offering the invention for sale. This is called the grace period, and “it’s critical to small inventors,” she said. Feinstein cited a letter from last year from 108 start-up and small businesses that said how important the grace period is to develop business and find funding.

    The grace period protects them during this period from disclosures or leaks of their idea as they learn the system. S.23 eliminates this grace period, she said, leaving only a grace period from “disclosure,” which is not defined and thus will likely be left to be defined by the courts. This will in turn lead to uncertainty which will chill investment, she argued. Universities might be somewhat protected by this, but not small inventors who normally would not publish a technical disclosure, as confidentiality is crucial for small companies.

    And according to Vermont Democratic Senator Patrick Leahy, one of the co-sponsors of the bill with Republican Sens. Orrin Hatch of Utah and Chuck Grassley of Iowa, the bill will boost US innovation and jobs. The transition of the US patent system to a first-inventor-to-file system, aims to “ensure that the USPTO has the funds necessary to process the backlog of more than 700,000 pending patent applications,” said a release.

    The Biotechnology Industry Organization backed the bill in a release on 8 March, stating that “patents are often the main assets of small biotech companies, and they rely on this intellectual property to attract investors to fund the lengthy and expensive research and development process necessary to bring breakthrough new therapies and other biotech products to patients and consumers.”

    And after years of trying, there are still some doubters about passage of a new patent law in 2011, according to Harold Wegner, partner at Foley & Lardner LLP, as Senate passage is just the first step towards the enactment of the new law, and the House of Representatives “clearly will not rubber stamp the Senate bill and will reach its own legislative solution.”

    William New may be reached at wnew@ip-watch.ch.

    Catherine Saez may be reached at info@ip-watch.ch.

     


    Leave a Reply

    We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website. By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

    We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website.

    By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

    1. You agree that you are fully responsible for the content that you post. You will not knowingly post content that violates the copyright, trademark, patent or other intellectual property right of any third party or which you know is under a confidentiality obligation preventing its publication and that you will request removal of the same should you discover that you have violated this provision. Likewise, you may not post content that is libelous, defamatory, obscene, abusive, that violates a third party's right to privacy, that otherwise violates any applicable local, state, national or international law, that amounts to spamming or that is otherwise inappropriate. You may not post content that degrades others on the basis of gender, race, class, ethnicity, national origin, religion, sexual preference, disability or other classification. Epithets and other language intended to intimidate or to incite violence are also prohibited. Furthermore, you may not impersonate others.

    2. You understand and agree that Intellectual Property Watch is not responsible for any content posted by you or third parties. You further understand that IP Watch does not monitor the content posted. Nevertheless, IP Watch may monitor the any user-generated content as it chooses and reserves the right to remove, edit or otherwise alter content that it deems inappropriate for any reason whatever without consent nor notice. We further reserve the right, in our sole discretion, to remove a user's privilege to post content on our site. IP Watch is not in any manner endorsing the content of the discussion forums and cannot and will not vouch for its reliability or otherwise accept liability for it.

    3. By submitting any contribution to IP Watch, you warrant that your contribution is your own original work and that you have the right to make it available to IP Watch for all purposes and you agree to indemnify IP Watch, its directors, employees and agents against all damages, legal fees and others expenses that may be incurred by IP Watch as a result of your breach of warranty or of these terms.

    4. You further agree not to publish any personal information about yourself or anyone else (for example telephone number or home address). If you add a comment to a blog, be aware that your email address will be apparent.

    5. IP Watch will not be liable for any loss including but not limited to the following (whether such losses are foreseen, known or otherwise): loss of data, loss of revenue or anticipated profit, loss of business, loss of opportunity, loss of goodwill or injury to reputation, losses suffered by third parties, any indirect, consequential or exemplary damages.

    6. You understand and agree that the discussion forums are to be used only for non-commercial purposes. You may not solicit funds, promote commercial entities or otherwise engage in commercial activity in our discussion forums.

    7. You acknowledge and agree that you use and/or rely on any information obtained through the discussion forums at your own risk.

    8. For any content that you post, you hereby grant to IP Watch the royalty-free, irrevocable, perpetual, exclusive and fully sub-licensable license to use, reproduce, modify, adapt, publish, translate, create derivative works from, distribute, perform and display such content in whole or in part, world-wide and to incorporate it in other works, in any form, media or technology now known or later developed.

    9. These terms and your posts and contributions shall be governed and interpreted in accordance with the laws of Switzerland (without giving effect to conflict of laws principles thereof) and any dispute exclusively settled by the Courts of the Canton of Geneva.

     

     
    Your IP address is 50.16.108.167